SGCB and chronic kidney disease: This hypothesis is corroborated by research conducted in animal models of CKD [75], where sGC activators such as cinaciguat [64,76,77], runcaciguat [67,72,78], and avenciguat [79,80,81] have been shown to reduce proteinuria, morphological kidney damage, and biomarkers of renal injury, irrespective of CKD etiologies.